| Literature DB >> 17981377 |
Bangalore Jayakrishnappa Mahendra1, Shampur Narayan Madhusudana, Doddabele Hanumanthaiah Ashwathnarayana, Gadey Sampath, Soma Subhra datta, Mysore Kalappa Sudarshan, Gonibeedu Manjunatah Venkatesh, Kader Muhamuda, Gangaboraiah Bilagumba, Manjula Shamanna.
Abstract
Purified duck embryo vaccine (PDEV, Vaxirab) for rabies prophylaxis is now indigenously manufactured in India under technology transfer from Berna Biotech who made the original PDEV (Lyssavac). In the present study we have compared the two vaccines in terms of safety, immunogenicity and tolerance. The study was conducted in 220 adult healthy volunteers. It was observed that both vaccines produced neutralizing antibody titers (as determined by rapid fluorescent focus inhibition test, RFFIT) more than 0.5 IU/mL (minimum level for seroconversion) on all days tested but the titers on days 90 and 180 were significantly higher with Lyssavac. The adverse reactions produced were slightly more with Lysssavac but both vaccines were well tolerated. In conclusion, the indigenously produced PDEV (Vaxirab) was found to be equally safe and immunogenic as the original PDEV (Lyssavac) manufactured at Switzerland.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17981377 DOI： 10.1016/j.vaccine.2007.10.002
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641